Charles Schwab Investment Management Inc Praxis Precision Medicines, Inc. Transaction History

Charles Schwab Investment Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 09, 2023	SELL	$0.83 - $1.18 $89,759 - $127,609	-108,144 Reduced 83.64%	21,152 $24,000
Q1 2023 May 11, 2023	BUY	$0.8 - $4.98 $15,146 - $94,286	18,933 Added 17.16%	129,296 $104,000
Q4 2022 Feb 13, 2023	BUY	$1.88 - $36.45 $49,214 - $954,188	26,178 Added 31.1%	110,363 $262,000
Q3 2022 Nov 14, 2022	SELL	$2.5 - $37.95 $435,327 - $6.61 Million	-174,131 Reduced 67.41%	84,185 $192,000
Q2 2022 Aug 15, 2022	BUY	$1.75 - $11.34 $7,246 - $46,958	4,141 Added 1.63%	258,316 $633,000
Q1 2022 May 13, 2022	BUY	$10.21 - $20.29 $65,486 - $130,140	6,414 Added 2.59%	254,175 $2.6 Million
Q4 2021 Feb 11, 2022	BUY	$16.76 - $22.99 $165,018 - $226,359	9,846 Added 4.14%	247,761 $4.88 Million
Q3 2021 Nov 16, 2021	BUY	$13.15 - $22.56 $1.55 Million - $2.67 Million	118,196 Added 98.73%	237,915 $4.4 Million
Q2 2021 Aug 16, 2021	BUY	$18.28 - $33.05 $860,457 - $1.56 Million	47,071 Added 64.79%	119,719 $2.19 Million
Q1 2021 May 17, 2021	BUY	$29.34 - $60.2 $84,733 - $173,857	2,888 Added 4.14%	72,648 $2.38 Million
Q4 2020 Feb 16, 2021	BUY	$27.25 - $55.82 $1.9 Million - $3.89 Million	69,760 New	69,760 $3.84 Million

75K

Ticker PRAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,576,100
Market Cap $3.26B
Description
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of ...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.